Clinical trial
Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's…
NCT00021723 · JANSSEN Alzheimer Immunotherapy Research & Development, LLC, Industry · Terminated
Key facts
| NCT number | NCT00021723 |
|---|---|
| Title | Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease |
| Lead sponsor | JANSSEN Alzheimer Immunotherapy Research & Development, LLC, Industry |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Biological |
| Interventions | AN-1792 also known as AIP-001 |
| Enrollment | 375 |
| Start date | Sep 1, 2001 |
| Completion | Sep 1, 2003 |
| First posted | Aug 6, 2001 |
| Last update posted | Sep 24, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: